Advanced biologics technology platform for next-gen immunotherapies
Discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers
Allogeneic CAR T (AlloCAR T ™) therapies for cancer
Integrated gene therapy company advancing medicines into the clinic
A novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs
Developing life-transforming therapies for patients with serious muscle diseases.
Gene editing and gene therapy platform to treat rare genetic diseases.
Pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer
Developing novel therapies for rare skeletal diseases
Providing high-quality Applied Behavior Analysis therapy and services to individuals diagnosed with autism spectrum disorder
Precision oncology approach to treat genomically defined cancers
Pursuing therapies against some of the most intractable cancer targets
Developing cell therapies to treat autoimmune diseases
Creating a new class of gene therapies by targeting disease-causing messenger RNA
Personalized T cell therapies to treat cancer
Leveraging neuroscience to develop novel therapeutics for dry eye disease and other ophthalmic conditions.
Personalized personalized neoTCR-T cell therapies for cancer.
Modulating myeloid cells in the tumor microenvironment to enhance antitumor immunity
Precision medicine approach to treating neurological disorders
Supporting biopharmaceutical clients through clinical development and commercialization
Targeting the underlying genetic cause of disease for underserved patients.
Target Engaged: Broadening the reach and impact of precision medicine for oncology.
Cell-free manufacturing platform to develop advanced protein therapeutics for cancer
Transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies
Developing novel therapies for the prevention and treatment of metastatic cancer
Make a meaningful difference in patients’ lives
© 2021 Vida Ventures, LLC